IN2012DN03418A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03418A
IN2012DN03418A IN3418DEN2012A IN2012DN03418A IN 2012DN03418 A IN2012DN03418 A IN 2012DN03418A IN 3418DEN2012 A IN3418DEN2012 A IN 3418DEN2012A IN 2012DN03418 A IN2012DN03418 A IN 2012DN03418A
Authority
IN
India
Prior art keywords
induces
immunogenic composition
whole
response
primarily antibody
Prior art date
Application number
Other languages
English (en)
Inventor
Richard Malley
Porter Anderson
Yingjie Lu
George A Robertson
Mark Alderson
Jean-Francois Lucien Maisonneuve
Andrea Maria Tate
Oliverira Dias Waldely De
Goncalves Viviane Maimoni
Original Assignee
Childrens Medical Center
Path Vaccine Solutions
Fundacao Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center, Path Vaccine Solutions, Fundacao Butantan filed Critical Childrens Medical Center
Publication of IN2012DN03418A publication Critical patent/IN2012DN03418A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN3418DEN2012 2009-10-09 2010-10-12 IN2012DN03418A (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25034809P 2009-10-09 2009-10-09
US38042910P 2010-09-07 2010-09-07
PCT/US2010/052298 WO2011044576A2 (en) 2009-10-09 2010-10-12 Selectively disrupted whole-cell vaccine

Publications (1)

Publication Number Publication Date
IN2012DN03418A true IN2012DN03418A (de) 2015-10-23

Family

ID=43857436

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3418DEN2012 IN2012DN03418A (de) 2009-10-09 2010-10-12

Country Status (5)

Country Link
US (1) US9827299B2 (de)
EP (1) EP2485764A4 (de)
CN (1) CN102648003B (de)
IN (1) IN2012DN03418A (de)
WO (1) WO2011044576A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3165531B1 (de) 2010-03-12 2020-11-25 Children's Medical Center Corporation Immunogene zusammensetzung, vakzin und deren verwendung
JPWO2012157699A1 (ja) * 2011-05-18 2014-07-31 味の素株式会社 動物用免疫賦活剤、それを含む飼料及びその製造方法
CA2900008C (en) 2013-02-07 2025-10-07 Children's Medical Center Corporation PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE
IL281204B2 (en) 2018-09-12 2025-07-01 Affinivax Inc Multivalent pneumococcal vaccines
US20230226172A1 (en) * 2020-06-12 2023-07-20 Schossau M. Tom Inactivation of Genome Enveloped within Coronavirus Spherical or Pleomorphic Particles or Shells to Form a Vaccine
AU2022342080A1 (en) 2021-09-09 2024-03-28 Affinivax, Inc. Multivalent pneumococcal vaccines
CN117756959B (zh) * 2024-02-22 2024-05-14 北京民海生物科技有限公司 一种肺炎链球菌荚膜多糖的制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6612233A (de) * 1966-08-30 1968-03-01
NL7012832A (de) * 1970-08-29 1972-03-02
US3852420A (en) * 1971-01-20 1974-12-03 Richardson Merrell Inc Equine strangles vaccine and method of preparing and using the same
FR2174745A1 (en) * 1972-03-09 1973-10-19 Inst Elevage Med Vet Mixed veterinary vaccine - active against symptomatic and bacterial anthrax
US3920811A (en) * 1972-12-22 1975-11-18 Cutter Lab Adjuvant compositions
US4675176A (en) 1983-12-12 1987-06-23 Norden Laboratories Moraxella bovis protease vaccine
US5281392A (en) * 1986-03-10 1994-01-25 Rubinstein Alan I Method for disinfecting red blood cells, blood products, and corneas
DE3715840A1 (de) * 1987-05-12 1988-12-01 Boehringer Mannheim Gmbh Fuer ein lytisch wirksames, chimaeres protein kodierende rekombinante dna und ihre verwendung
GB8906795D0 (en) * 1989-03-23 1989-05-10 Carroll Noel Method of preparing vaccines
ATE123417T1 (de) * 1989-10-06 1995-06-15 Janos Szabo Pharmazeutische zusammensetzungen zur behandlung von hauterkrankungen, insbesondere pyogener und atopischer dermatitis und verfahren zu deren herstellung.
US5418130A (en) 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
EP0674905B1 (de) 1990-06-07 2002-12-11 Bayer Corporation Bacterin zur Behandlung von Lebernekrose verursacht durch F. Necrophorum
US6042838A (en) * 1991-02-15 2000-03-28 Uab Research Foundation immunogenic compositions for mucosal administration of pneumococcal surface protein A (PspA)
AU4114893A (en) * 1992-04-27 1993-11-29 Michigan State University Method for producing a bacterial vaccine and novel vaccines produced thereby
US6764682B1 (en) * 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
AUPN175495A0 (en) * 1995-03-14 1995-04-13 University Of New England, The Method and composition for the prevention of the over production of acid
US6743430B1 (en) * 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
DE19603649A1 (de) * 1996-02-01 1997-08-07 Werner Lubitz Rekombinante Expression von S-Layer-Proteinen
CA2271720A1 (en) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
IT1296148B1 (it) * 1996-11-22 1999-06-09 Renata Maria Anna Ve Cavaliere Uso di batteri lattici per accrescere il livello delle ceramidi della pelle e delle mucose, e composizioni dermatologiche e cosmetiche atte
US6416959B1 (en) * 1997-02-27 2002-07-09 Kenneth Giuliano System for cell-based screening
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US5958414A (en) 1997-09-03 1999-09-28 Heska Corporation Composition to protect a mammal against Bartonella henselae infection
JP2001520205A (ja) 1997-10-20 2001-10-30 バイエル・コーポレーシヨン ネオスポラワクチン
US7172762B1 (en) 1999-01-29 2007-02-06 Pfizer Inc. Erysipelothrix rhusiopathiae antigens and vaccine compositions
AU782508B2 (en) 1999-11-08 2005-08-04 Biomune Vaccines for mycoplasma bovis and methods of use
DE10003241A1 (de) * 2000-01-26 2001-08-02 Werner Lubitz Verschließen von Bakterienghosts
US6378677B1 (en) * 2000-10-03 2002-04-30 Honda Giken Kogyo Kabushiki Kaisha Power transmission device having electromagnetic clutch
AU2002367976B2 (en) * 2001-06-05 2007-06-21 The Regents Of The University Of Michigan Nanoemulsion vaccines
DK1395648T3 (da) * 2001-06-11 2009-08-03 Applied Nanosystems Bv Fremgangsmåder til binding af AcmA-type proteinankerfusioner til cellevægsmateriale af mikroorganismer
ATE462779T1 (de) 2001-07-11 2010-04-15 Lubitz Werner Prof Dr Nukleinsäurefreie ghost zusammensetzungen
DK1446489T3 (da) * 2001-10-15 2012-05-14 Engeneic Molecular Delivery Pty Ltd Intakte miniceller som vektorer for DNA-overførsel og genterapi in vitro og in vivo
US20060121058A1 (en) * 2002-08-08 2006-06-08 Children's Medical Center Corporation Anti-pneumococcal preparations
JPWO2004096247A1 (ja) * 2003-04-28 2006-07-13 積水化学工業株式会社 サイトカイン誘導用具及びサイトカイン誘導方法
US7204993B2 (en) * 2004-03-18 2007-04-17 The United States Of America As Represented By The Secretary Of Agriculture Streptococcus agalactiae vaccine
US7211428B1 (en) * 2004-05-18 2007-05-01 Council Of Scientific And Industrial Research Strain of Bacillus as a bioinoculant
US7291276B1 (en) * 2004-06-21 2007-11-06 Winston Company, Inc. Controlled production and release of oxygen activated biocide into holding tanks for RV's, boats and the like
US20060003454A1 (en) * 2004-07-02 2006-01-05 Conjugon, Inc. Non-dividing donor cells for gene transfer
CN101060852A (zh) * 2004-08-17 2007-10-24 亨特免疫有限公司 口服灭活疫苗及其提供方法
EP1824973A1 (de) * 2004-12-14 2007-08-29 Alk-Abello A/S Pharmazeutische zusammensetzung mit eine heterologe proteinartige verbindung präsentierender bakterienzelle
JP4909264B2 (ja) * 2005-04-01 2012-04-04 独立行政法人理化学研究所 経鼻ワクチン
EP2371843B1 (de) * 2005-05-19 2014-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Funktionelle Epitope des Pneumokokken-Antigens und deren Nutzung
EP1746103A1 (de) * 2005-07-20 2007-01-24 Applied NanoSystems B.V. Bifunktionelle Protein-Anker
EP1942932B1 (de) * 2005-08-08 2013-05-08 Oregon Health and Science University Inaktivierung von erregern mit wasserstoffperoxid zur produktion eines impfstoffes
WO2007052163A2 (en) 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
BRPI0621760A2 (pt) * 2006-07-10 2011-12-20 Univ Arizona State molécula de ácido nucléico recombinante que não ocorre naturalmente, célula recombinante, composição imunogênica, anticorpo, método para detectar a presença de proteìna pilus de campylobacter e método para detectar um anticorpo que se liga especificamente a uma proteìna pilus de campylobacter jejuni
CN101730543B (zh) * 2007-07-23 2014-02-12 疫苗研究国际有限公司 灭活的葡萄球菌全细胞疫苗
EP2349209A2 (de) * 2008-09-26 2011-08-03 Nanobio Corporation Therapeutische zusammensetzungen in nanoemulsionsform und anwendungsverfahren dafür
TW201043242A (en) * 2009-03-26 2010-12-16 Intervet Int Bv Vaccine for protection against Streptococcus suis bacteria of various serotypes
US8551749B2 (en) * 2009-04-23 2013-10-08 The Invention Science Fund I, Llc Device including bone cage and method for treatment of disease in a subject
WO2010132833A1 (en) * 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
SG179037A1 (en) * 2009-09-10 2012-04-27 Merial Ltd New vaccine formulations comprising saponin-containing adjuvants
JP2013512692A (ja) * 2009-12-07 2013-04-18 シナプティック リサーチ，リミテッド ライアビリティ カンパニー プロテアーゼ活性阻害剤の同定とプロテアーゼ活性の存在を測定するための方法

Also Published As

Publication number Publication date
CN102648003B (zh) 2016-01-13
WO2011044576A3 (en) 2011-08-18
EP2485764A2 (de) 2012-08-15
WO2011044576A2 (en) 2011-04-14
US9827299B2 (en) 2017-11-28
CN102648003A (zh) 2012-08-22
US20120251577A1 (en) 2012-10-04
EP2485764A4 (de) 2014-01-29

Similar Documents

Publication Publication Date Title
IL273607A (en) Humanized antibodies against liv-1, preparations containing them and their uses
MX2015005810A (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco.
WO2013063613A3 (en) Methods and compositions related to intracellular neutralization by igg
AU2016204319A1 (en) Methods and compositions for producing squalene using yeast
PH12013501942A1 (en) Antibody-drug conjugates
WO2010145792A8 (en) Bispecific antigen binding proteins
WO2011044576A3 (en) Selectively disrupted whole-cell vaccine
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
EP3038644A4 (de) Konjugationsverfahren stellenspezifischer antikörper und zusammensetzungen
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
MY170720A (en) Antibody formulations
WO2009135181A3 (en) Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
MY171841A (en) Antibody formulation
MX359639B (es) Metodos y composiciones para uso en tratamientos celulares.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
MY161909A (en) Anti-her3 antibodies and uses thereof
IL219801A (en) Anti-a4 antibody. 4c isolates, vectors encoded by them, methods of preparation, preparations containing them and their use
MX2013012184A (es) Composiciones formadoras de gel in situ.
WO2011142858A3 (en) Chlorotoxin variants, conjugates, and methods for their use
MX354924B (es) Molecula portadora que comprende un antigeno spr0096 y un spr2021.
MX2009013056A (es) Composiciones aglutinantes no dulces y metodos de hacer y usar las mismas.
WO2010088395A3 (en) Synthetic agonists of tlr 9